

Enrico Derenzini

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5819741/enrico-derenzini-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90
papers

2,134
citations

25
h-index

44
g-index

97
ext. papers

2,407
ext. citations

4.3
avg, IF

4.1
L-index

#	Paper	IF	Citations
90	Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4293-7	2.2	244
89	Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. <i>Annals of Oncology</i> , 2010 , 21, 860-863	10.3	147
88	Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1781-7	2.2	143
87	Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 462-6	2	92
86	Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. <i>Cancer Treatment Reviews</i> , 2006 , 32, 214-28	14.4	81
85	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , 2008 , 9, 352-8	21.7	73
84	The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. <i>Blood</i> , 2012 , 119, 4017-25	2.2	70
83	Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2008 , 113, 2496-503	6.4	62
82	A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. <i>Annals of Oncology</i> , 2008 , 19, 769-73	10.3	60
81	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013 , 98, 1232-6	6.6	57
80	Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2011 , 117, 1010-8	6.4	51
79	Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. <i>Clinical Cancer Research</i> , 2010 , 16, 3998-4004	12.9	51
78	The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2011 , 1, e46	7	51
77	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 6553-69	3.3	47
76	Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. <i>Cancers</i> , 2019 , 11,	6.6	43
75	Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1585-8	1.9	43
74	A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. <i>Cancer</i> , 2008 , 112, 856-62	6.4	41

73	The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 Family inhibitors. <i>Experimental Hematology</i> , 2011 , 39, 1007-1017.e1	3.1	38
72	Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. <i>Cancer</i> , 2010 , 116, 4788-92	6.4	38
71	Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. <i>Oncotarget</i> , 2017 , 8, 14017-14028	3.3	36
70	Umbralisib, a Dual PI3K/CK1 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1609-1618	2.2	36
69	MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. <i>Annals of Oncology</i> , 2010 , 21, 1173-1178	10.3	33
68	Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016 , 7, 53377-53391	3.3	32
67	Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 775-85	5.9	30
66	Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF- κ B-Controlled Oxidative Stress Responses. <i>Cancer Research</i> , 2016 , 76, 377-89 ^{10.1}		27
65	Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. <i>Hematological Oncology</i> , 2013 , 31, 183-8	1.3	25
64	FDG-PET in the assessment of patients with follicular lymphoma treated by ibrutinomab tiuxetan Y 90: multicentric study. <i>Annals of Oncology</i> , 2010 , 21, 1877-1883	10.3	25
63	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 125	22.4	24
62	Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 321-5	2	24
61	A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ibrutinomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. <i>Annals of Oncology</i> , 2012 , 23, 415-20	10.3	24
60	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. <i>Oncotarget</i> , 2016 , 7, 12951-61	3.3	24
59	Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. <i>Oncologist</i> , 2014 , 19, 746-50	5.7	22
58	Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 188-94	3.8	21
57	Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. <i>Hematological Oncology</i> , 2013 , 31, 223-4	1.3	21
56	BET Inhibition-Induced GSK3 β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. <i>Cell Reports</i> , 2018 , 24, 2155-2166	10.6	20

55	Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. <i>Hematological Oncology</i> , 2013 , 31, 179-82	1.3	17
54	Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2318-21	1.9	15
53	Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. <i>Genome Medicine</i> , 2011 , 3, 26	14.4	15
52	Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7, 566-72		15
51	Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 258-65	2	13
50	Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. <i>Leukemia and Lymphoma</i> , 2009 , 50, 481-4	1.9	13
49	Bendamustine: role and evidence in lymphoma therapy, an overview. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1471-8	1.9	12
48	Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. <i>British Journal of Haematology</i> , 2013 , 163, 681-3	4.5	12
47	Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 258-61	2	12
46	Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). <i>Annals of Oncology</i> , 2012 , 23, 805-807	10.3	12
45	Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. <i>Leukemia and Lymphoma</i> , 2008 , 49, 159-62 ¹⁹		12
44	Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 493-5	2	11
43	Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 1620-7	8.8	10
42	Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2009 , 84, 849-50	7.1	10
41	VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2167-71	1.9	9
40	Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 75	22.4	9
39	Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1695-701	4.7	8
38	High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. <i>BMC Cancer</i> , 2015 , 15, 879	4.8	8

37	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2011 , 43, 1015-21	3.3	8
36	CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. <i>Journal of Neuro-Oncology</i> , 2009 , 95, 135-139	4.8	8
35	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2021 ,	2.2	5
34	Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas. <i>Cells</i> , 2021 , 10,	7.9	5
33	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2021 ,	10.7	5
32	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019 , 185, 330-334	4.5	4
31	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1824-9	1.9	4
30	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015 , 4, 24	7.8	3
29	Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. <i>British Journal of Haematology</i> , 2014 , 166, 625-8	4.5	3
28	In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012 , 120, 1496-1496	2.2	3
27	The Role of Interim-PET and Final-PET in the Outcome of Peripheral T-Cell Lymphoma (PTCL) Treated At the Diagnosis with CHOP.. <i>Blood</i> , 2012 , 120, 2721-2721	2.2	3
26	Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.. <i>Blood</i> , 2009 , 114, 1659-1659	2.2	2
25	Dissecting diffuse large B-cell lymphomas of the "not otherwise specified" type: the impact of molecular techniques. <i>F1000Research</i> , 2018 , 7,	3.6	2
24	Integrated safety analysis of umbralisib, a dual PI3K/CHK1 inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021 , 5, 5332-5343	7.8	2
23	Slow evolution of liver metastasis from colon cancer. <i>Digestive and Liver Disease</i> , 2005 , 37, 628-9	3.3	1
22	Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies. <i>Blood</i> , 2018 , 132, 676-676	2.2	1
21	The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction. <i>Blood</i> , 2010 , 116, 2850-2850	2.2	1
20	The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). <i>Blood</i> , 2011 , 118, 76-76	2.2	1

19	Primary Mediastinal Large B-Cell Lymphoma: Investigation On The Role Of Rituximab and PET During Treatment. <i>Blood</i> , 2013 , 122, 3046-3046	2.2	1
18	Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study. <i>Blood</i> , 2016 , 128, 3003-3003	2.2	1
17	Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2015 , 126, 2725-2725	2.2	1
16	The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011 , 118, 2732-2732	2.2	1
15	RALE051: a novel established cell line of sporadic Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1252-1255	1.9	
14	Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1791-3	1.9	
13	Langerhans Cell Histiocytosis: A Single Institution Retrospective Analysis of Eleven Patients. <i>Blood</i> , 2014 , 124, 5458-5458	2.2	
12	The Treatment of Primary Mediastinal Large B-Cell Lymphoma: A Two Decades Monocentric Experience on 98 Patients. <i>Blood</i> , 2014 , 124, 4440-4440	2.2	
11	Efficacy and Safety of Biosimilar Epoetin Alpha in Patients with Chronic Lymphoproliferative Syndromes and Chemotherapy-Induced Anemia: An Observational, Retrospective, Monocentric Analysis. <i>Blood</i> , 2014 , 124, 5478-5478	2.2	
10	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. <i>Blood</i> , 2015 , 126, 3937-3937 ^{2,2}		
9	The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 2478-2478	2.2	
8	Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma. <i>Blood</i> , 2016 , 128, 293-293	2.2	
7	The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma. <i>Blood</i> , 2011 , 118, 2731-2731	2.2	
6	Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.. <i>Blood</i> , 2011 , 118, 1604-1604	2.2	
5	Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma.. <i>Blood</i> , 2012 , 120, 3019-3019	2.2	
4	Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients.. <i>Blood</i> , 2012 , 120, 2736-2736 ^{2,2}		
3	Genomic Instability and Activation Of The DNA Damage Response Pathway Is An Independent Predictor Of Poor Prognosis, Is Associated With MYC Expression and Is a Promising Target For Therapy In Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2013 , 122, 3015-3015	2.2	
2	Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma. <i>Blood</i> , 2013 , 122, 5543-5543 ^{2,2}		

- 1 Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma. *Bone Marrow Transplantation*, **2021**, 56, 2280-2283 4-4